Literature DB >> 16344670

Increased pulmonary artery pressures among adolescents with sickle cell disease.

Mary Nell Suell1, Louis I Bezold, M Fatih Okcu, Donald H Mahoney, Felix Shardonofsky, Brigitta U Mueller.   

Abstract

The prevalence of pulmonary hypertension (PHT) among adolescents with sickle cell disease (SCD) is unknown. A tricuspid regurgitant (TR) jet peak velocity of 2.5 m/s or more is a screening test for PHT. The authors retrospectively reviewed echocardiograms and clinical data of adolescents followed at the Texas Children's Sickle Cell Center. Of 80 evaluable adolescents with SCD and echocardiogram data, 21 (26%) had a TR jet velocity of 2.5 m/s or more. Of these 21 patients with PHT, 12 (57%) had an echocardiogram performed during an inpatient stay for vaso-occlusive crisis (n = 6), acute chest syndrome (n = 4), fever (n = 1), or seizures (n = 1), and 9 (43%) had an echocardiogram performed as an outpatient in a baseline state of health. Elevation of pulmonary artery pressures was common in this adolescent cohort, but clinical symptoms were rare. Prospective study is warranted to determine the prevalence and course of elevated pulmonary artery pressures in this age group.

Entities:  

Mesh:

Year:  2005        PMID: 16344670     DOI: 10.1097/01.mph.0000194022.17968.bf

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  11 in total

Review 1.  Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment.

Authors:  Raymond L Benza
Journal:  Lung       Date:  2008-05-10       Impact factor: 2.584

Review 2.  Antibiotics for treating acute chest syndrome in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno; Jennifer M Knight-Madden
Journal:  Cochrane Database Syst Rev       Date:  2015-03-06

3.  Left ventricular hypertrophy and diastolic dysfunction in children with sickle cell disease are related to asleep and waking oxygen desaturation.

Authors:  Mark C Johnson; Fenella J Kirkham; Susan Redline; Carol L Rosen; Yan Yan; Irene Roberts; Jeanine Gruenwald; Jan Marek; Michael R DeBaun
Journal:  Blood       Date:  2010-04-08       Impact factor: 22.113

Review 4.  Pulmonary hypertension in sickle cell disease: relevance to children.

Authors:  Gregory J Kato; Onyinye C Onyekwere; Mark T Gladwin
Journal:  Pediatr Hematol Oncol       Date:  2007 Apr-May       Impact factor: 1.969

5.  Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease.

Authors:  Niti Dham; Gregory Ensing; Caterina Minniti; Andrew Campbell; Manuel Arteta; Sohail Rana; Deepika Darbari; Mehdi Nouraie; Onyinye Onyekwere; Malgorzata Lasota; Gregory J Kato; Mark T Gladwin; Oswaldo Castro; Victor Gordeuk; Craig Sable
Journal:  Am J Cardiol       Date:  2009-06-24       Impact factor: 2.778

Review 6.  Pulmonary arterial hypertension in children: a medical update.

Authors:  Erika B Rosenzweig; Robyn J Barst
Journal:  Indian J Pediatr       Date:  2009-04-18       Impact factor: 1.967

7.  Pulmonary hypertension in children and adolescents with sickle cell disease.

Authors:  O C Onyekwere; A Campbell; M Teshome; S Onyeagoro; C Sylvan; A Akintilo; S Hutchinson; G Ensing; P Gaskin; G Kato; S Rana; J Kwagyan; V Gordeuk; J Williams; O Castro
Journal:  Pediatr Cardiol       Date:  2007-08-07       Impact factor: 1.655

8.  Doppler echocardiographic assessment of pulmonary artery pressure in children with sickle cell anaemia.

Authors:  Moriam Omolola Lamina; Barakat Adeola Animasahun; Ijeoma Nnena Akinwumi; Olisamedua Fidelis Njokanma
Journal:  Cardiovasc Diagn Ther       Date:  2019-06

9.  Pulmonary hypertension in hemolytic anemias.

Authors:  Shannon Wahl; Elliott Vichinsky
Journal:  F1000 Med Rep       Date:  2010-02-11

Review 10.  Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders.

Authors:  Claudia R Morris; Mark T Gladwin; Gregory J Kato
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.